Assessing mean apnea-hypopnea duration (MAD) in patients with OSA yields hypoxemia and symptom burden data not provided by the AHI or ODI.

At World Sleep 2025, Robson Capasso, MD, of Stanford University in California, challenged the field's reliance on the apnea-hypopnea index (AHI) as the primary measure of treatment success in ...

Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...

Sleep apnea can result in daytime fatigue and irritability. Obstructive Sleep Apnea, defined as having frequent episodes of ...

As nights get hotter around the globe due to climate change, the prevalence of sleep apnea is expected to increase by as much ...

Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...

More than half of people with hypertension also have sleep apnea, leading to nighttime oxygen deprivation that can place undue stress on the heart, especially in the winter, a doctor said. As ...

Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.